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ABSTRACT 
 
RELATIONSHIPS BETWEEN OBJECTIVELY MEASURED PHYSICAL ACTIVITY AND STOOL 
METABOLOME IN INDIVIDUALS AT HIGH RISK FOR COLORECTAL CANCER 
 
Physical activity is known to reduce the risk of colorectal cancer and adenomatous polyp 
recurrence. Targeted metabolomic profiling of the stool metabolome may provide insight to the 
mechanistic links between physical activity and colorectal cancer. This study utilized baseline physical 
activity and metabolomics data from a dietary fiber intervention for individuals at high risk for colorectal 
cancer. Participants (N=21), 59±9 years, BMI 28.1±3.35 wore an activPALÔ accelerometer for 7 
consecutive days, provided a stool sample, and a 3-day dietary log. Stool bile acids and short chain fatty 
acids were quantified with gas chromatography mass spectroscopy and ultra-high performance liquid-
chromatography tandem mass spectrometry. Linear regression models examined relationships between 
light intensity physical activity minutes, moderate to vigorous physical activity minutes, MET-hours per 
day, and sedentary minutes, with abundances of short chain fatty acids and bile acids while accounting for 
dietary fiber intake. Light intensity PA minutes predicted butyrate and propionate abundance when 
accounting for dietary fiber. MVPA predicted deoxycholic acid and ursodeoxycholic acid abundance. 
These data suggest that both low intensity PA and MVPA may both have implications for colorectal 
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With 135,000 new cases of colorectal cancer and over 50,000 colorectal cancer related deaths in 
2017, colorectal cancer is the third most common, and the second leading cause of death from cancer in 
the United States.1.2 Colorectal cancer is a cancer of the large intestine or rectum that typically originates 
from adenomatous polyps in 90-95% of all large bowel tumors. Adenomatous polyps form from 
uncontrolled crypt cell division, and appear as circumscribed lumps of epithelial dysplasia.3 Polyps can be 
discovered with a colonoscopy, and the American Cancer Society (ACS), recommends that asymptomatic 
individuals should undergo a colonoscopy at age 45, and every 10 years thereafter should no polyps be 
found, or every 3 years thereafter if polyps are found.4 Colorectal cancer is found in nearly all races and 
both sexes, but there is a marked difference among geographic location. Adenomatous polyps are rare in 
Africa and some Asian countries, but are very common in Western countries. Colorectal cancer rates 
generally correlate with the adoption of a western lifestyle, but mortality is much lower in higher income 
countries with access to screening techniques.5  
The majority of colorectal cancer incidence is linked to modifiable lifestyle factors. Only 5-10% 
of incidences of colorectal cancer are due to hereditary conditions, such as Lynch Syndrome and Familial 
Adenomatous Polyposis.6 According to the World Cancer Research Fund, 30-40% of all cancers can be 
prevented by appropriate diet and exercise, and this figure may be as high as 70% for colorectal cancer.7 
Physical activity is known to be protective against a multitude of cancer types including colon and rectal 
cancers,8-10 and may also protect against adenomatous polyp recurrence.10,11 Physical activity is known to 
induce many systemic effects,12,13 and several proposed mechanisms exist by which physical activity may 
prevent colorectal cancer. Physical activity can reduce systemic inflammatory status, as well as increase 
anti-inflammatory cytokines, catecholamines, and reduce adipokine and pro-inflammatory cytokine 
production.14 Further, physical activity reduces bowel transit time,15 and increases bowel motility,14 which 
are both protective against colorectal cancer progression. Additionally, hyperinsulinemia may play a role 
in epithelial cell growth16 and physical activity is known to increase insulin sensitivity. However, recent 
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work suggests that both microbial and innate metabolism may play a pivotal role in the colon and rectal 
microenvironment and affect colorectal cancer development.17,18 Thus, targeted metabolomics is a method 
that could help elucidate the relationship between physical activity and colorectal cancer prevention. 
Metabolomics is defined as “the scientific study of the set of metabolites present within an 
organism, cell, or tissue.”19 It includes lipids, amino acids, carbohydrates, peptides, energy metabolites, 
cofactors, vitamins, and exogenous compounds. Metabolomics is a unique approach because it allows one 
to examine both endogenous and exogenous compounds in a specific environment. This is important for 
understanding the role of the microbiome as well as host metabolism in progression of colorectal cancer. 
Targeted metabolomics allows for a unique approach to examining specific metabolites in absolute, rather 
than relative, abundance. Several metabolites in the stool have been associated with colorectal cancer, and 
they may be modifiable by physical activity.20,21 Targeted metabolomics is a unique approach that allows 
for quantification of absolute, rather than relative, abundance of metabolites of interest. Both short chain 
fatty acids and bile acids are possible mechanistic links between physical activity and colorectal cancer 
prevention.  
 Bile acids are biologic detergents synthesized in the liver, stored in the gall bladder, and secreted 
into the duodenum that facilitate the intestinal absorption of dietary lipids. The majority of bile acids are 
resorbed in the ileum. However, a small minority are passed to the colon for excretion in stool. Bile acids 
in the stool may be contraindicated due to possible carcinogenic and inflammatory mechanisms. In the 
colon, primary bile acids can be conjugated to secondary bile acids by gut microbes22,23. Deoxycholic acid 
(DCA), a secondary bile acid,  can activate proteosomal degradation of the tumor suppressor p53, 
selecting for cells resistant to apoptosis in spite of DNA damage.24 Further, DCA may cause membrane 
perturbations leading to the release of arachidonic acid. Arachidonic acid is converted by COX-2 or 
lipooxygenase to pro-inflammatory and pro-angiogenic prostaglandins and reactive oxygen species. 
These can damage DNA and inhibit DNA repair enzymes in colonic epithelial cells. Conversely, 
ursodeoxycholic acid may actually be preventive of colorectal cancer and is used as a supplement in 
individuals at high risk.20,25 Bile acids are modifiable by physical activity.20 Physical activity may help 
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reduce fecal bile acid concentration through several mechanisms. GI pancreatic hormones such as 
vasoactive intestinal polypeptide, motilin, and pancreatic polypeptide affect the motility of the large 
intestine.24 This can reduce transit time and thus increase bile acid secretion. Additionally, regular aerobic 
exercise reduces triglycerides, VLDL particle size, and LDL particle size.26 Caloric restriction has been 
shown to reduce bile acid synthesis but it is unknown if physical activity has the same effect and/or 
mechanism.27 
Short chain fatty acids, in particular propionate, acetate and butyrate, are associated with reduced 
risk of colorectal cancer and are modifiable by physical activity through intestinal mixing, increased 
anaerobic fermentation, increased gut motility, and increased expression of butyrate-acetoacetate coA 
transferase (BCoAT).21,28,29 Short chain fatty acids are produced by the gut microbiota during 
fermentation of non-digestible or partially digestible polysaccharides. Some butyrate producing bacteria 
include Clostridiales, Lachnospira, Rosebria, f_Lachnospiraceae, and Faecalibacterium.21 Butyrate has 
been studied for its role in nourishing the colon mucosa as well as its ability to help to prevent colon 
cancer. Butyrate and propionate, but not acetate, inhibit histone deacetylases in immune cells and 
colonocytes. Some possible mechanisms include promotion of cell differentiation, cell-cycle arrest and 
apoptosis of transformed colonocytes, inhibition of histone deacetylase, decreased transformation of 
primary to secondary bile acids because of colonic acidification.30  
It is well known that total physical activity can help prevent colorectal cancer and polyp 
recurrence, but it is unknown whether or not stool bile acids and short chain fatty acids provide a possible 
mechanistic link for this relationship. Further, it is unknown what type or intensity of physical activity has 
the strongest relationship with these aforementioned metabolites. Metabolic signatures associated with 
physical activity in populations with high risk for cancer development could be a useful tool to understand 
disease phenotypes and help to reduce cancer risk31,32.  
Only two previous studies have examined the effects of physical activity on the metabolome31,32, 
and none have examined the relationship between the metabolome and physical activity in the context of 
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colorectal cancer prevention. Thus, the purpose of this study is to examine relationships between physical 
activity and the stool metabolome in individuals at high risk for colorectal cancer.  
  
 






This study utilized baseline data from a pilot, randomized trial “Beans/bran Enriching Nutritional 
Eating For Intestinal health and Cancer Including Activity for Longevity (BENEFICIAL)”. Study visits 
occurred at the Human Performance Clinical Research Laboratory at Colorado State University. All 
individuals provided written consent prior to participation in the study, and study protocols were 
approved by Colorado State University (protocol # 17-7464H).  
Participants 
Study participants were recruited from the University of Colorado Health System, Centers for 
Gastroenterology, and via university and community-based email recruitment efforts. Participants were 
eligible if they met the following criteria: (1) a healthy adult (≥18 years of age) who had one or more 
adenomatous polyps removed within the previous 3 years , (2) had not received adjuvant treatment such 
as chemotherapy or radiotherapy with their surgical removal of polyps/tumors, (3) not pregnant or 
lactating, or planning to become pregnant during the study, (4) no history of food allergies and/or major 
dietary restrictions, (5) ability to complete study questionnaires in English, and food logs electronically, 
and (6) willing to provide blood, urine, and stool samples as required by study protocol.  
Sample Collection  
Stool samples were collected into a sterile urine cup within 24 hours before the lab visit. A 
sample of raw stool was immediately transferred to a 15mL conical tube and stored at -80°C until further 
analysis. The remaining stool was lyophilized. The urine cup lid was replaced with autoclaved aluminum 
foil containing small ventilation holes. Samples were lyophilized for 48-72 hours or until sample mass did 
not change over a 24-hour period.  
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Anthropometry 
Height, weight, were measured in light clothing without shoes, and used to calculate Body Mass 
Index (BMI) (kg/m2). Waist circumference was measured at the umbilicus. Each measurement was taken 
three times in succession by the same technician, and averaged.  
Cholesterol 
Twelve-hour fasted blood samples were collected between 7:00am and 11:00am. Blood was 
drawn through venipuncture into an EDTA tube (Greiner bio-one, Monroe, NC) and immediately stored 
on ice. Total cholesterol, HDL-Cholesterol, and LDL-Cholesterol were assessed in whole blood with 
PiccoloÒ Lipid Panel Plus (Abaxis, Inc, Union City, CA).  
Dietary Fiber Quantification 
 
Participants provided a 3-day dietary food log.33 All foods or beverages consumed and their 
quantities were recorded. Participants were asked to consume their habitual diet and record two week 
days and one weekend day. The food logs were analyzed using Nutritionist ProÔ (Axxya Systems, 
Redmond, WA) and each participants’ caloric intake, macronutrient and micronutrient consumption were 
estimated for each individual.  
Physical Activity 
Physical activit (PA) was measured using an activPAL accelerometer (PAL Technologies, 
Glasgow, Scotland). The activPAL quantifies free-living sedentary and ambulatory activities. It has been 
validated as one of the most accurate wearable activity monitors and has previously been used in healthy 
adults as well as cancer survivors.34-36 The activPAL activity monitor is a small device worn on the thigh 
that uses information about static and dynamic acceleration to 1) distinguish body posture as sitting/lying, 
standing and stepping and 2) estimate energy expenditure (EE) (expressed as metabolic equivalents 
(METs)).37 The activPAL was wrapped in a nitrile sleeve for waterproofing and attached to the anterior 
aspect of the right thigh with Tegaderm dressing. Participants wore the activPAL for 7 consecutive days, 
24 hours per day, for the week immediately following the baseline study visit. Participants were asked to 
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record times of activPAL removal and sleep/wake-up times. Data were downloaded using the 
activPAL software (v. 7.2.38 ) and summarized using the activpalProcessing package in R.38 Days of data 
collection required at least 600 min (10 h) of wear time to be considered valid. Non-wear periods were 
excluded from analyses; these were defined using participant logs and verified via visual inspection of the 
accelerometer data. A cadence based linear regression was used to estimate total MET hours and time 
spent in sedentary (METs <1.5), light (METs 1.5-2.99), and moderate-to-vigorous (METs³3) intensity 
activity per day.39 Each variable was summed between all valid days and divided by valid days to 
calculate daily values.  
  
Assessed for Eligibility: 
n=68 
Excluded (n=45) 
• Not interested (n=20) 
• Not a good time (n=10) 






• No stool sample (n=2) 




Figure 1: CONSORT Diagram: participants and stool samples used for metabolomic 
analysis 
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Targeted Metabolomics 
 
Stool metabolite extraction and targeted metabolic profiling occurred at the Colorado State 
University Proteomics & Metabolomics Facility using both ultra high-performance liquid 
chromatography tandem mass spectrometry (UPLC-MS/MS) and gas chromatography mass spectrometry 
(GS-MS). 
Short chain fatty acids: 
Samples arranged in a randomized order were extracted and injected to GCMS along with 7 
quality controls (QCs) that were generated from a pooled sample extract.  20 mg frozen stool samples, 
340 μL of cold 3 M HCl and 60 μL of internal standard solution containing 1 mg/mL of 
13
C2-acetic acid 
(Sigmal-Aldrich) and 0.5 mg/mL of 
13
C4-sodium butyrate (Santa Cruz Biotechnology) were added. 
Samples were vigorously shaken for 30 min, followed by sonication for 10 min in a cold water bath, and 
then centrifuged at 15,000 g for 15 min at 4°C. Supernatants (200 μL) were recovered, and added to 350 
μL MTBE, followed by vortexing for 5 s twice. About 60 μL of the top MTBE layer were recovered after 
centrifugation at 3,000 g for 5 min at 4°C, and stored at 4°C until analysis.  The MTBE extract (1 μL) of 
short chain fatty acids were injected into a Thermo Trace 1310 GC coupled to a Thermo ISQ-LT MS, at a 
5:1 split ratio. The inlet was held at 240°C. SCFA separation was achieved on a 30m DB-WAXUI 
column (J&W, 0.25 mm ID, 0.25 μm film thickness). Oven temperature was held at 100°C for 0.5 min, 
ramped at 10°C/min to 175°C, then ramped to 240°C at 40°C/min, and held at 240°C for 3 min. Helium 
carrier gas flow was held at 1.2 mL/min. Temperatures of transfer line and ion source were both held at 
250°C. SIM mode was used at a rate of 10 scans/sec under electron impact mode. Data were processed 
using Chromeleon software (version 7.2.8, Thermo). Internal standard, 
13
C2-acetic acid, was used to 
quantify acetic and propionic acid; 
13
C4-sodium butyrate was used to quantify other acids. Pooled QC 
samples were injected after every 6 injections. The CV of 6 QCs was 1.0-3.6%. Linearity with R
2 
>0.997 
was obtained from all the calibration curves. Limit of detection (LOD) and limit of quantification (LOQ) 
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were calculated using the standard deviation of blanks and the slope of calibration curve.  
Bile acids: 
Hydrolysis Solution: 100 mM NaOH, pH 13 
Extraction Solution: 100% Acetonitrile spiked with Internal Standards each at 400 ng/mL  
Standard Curve: All target analytes were prepared from dry stock at a concentration of 1 mg/ml in 100% 
ACN. A master mix of all target analytes was prepared in 100% ACN at a concentration of 0.1 mg/mL. 
Internal standards (Glycocholic acid-d4, Taurocholic acid-d5, and Deoxycholic acid-d4) were prepared at 
the same concentrations. Dilution series were made in 30% ACN, 70% 100 mM NaOH spiked with IS-
mix at 400 ng/mL. Starting concentration was 5,000 ng/mL. Low point concentration was 1 ng/mL, with 
an IS only zero point to calculate standard deviation of background signal.  
Extraction:  
Bile acids were extracted from stool samples in the presence of 0.1 M sodium hydroxide followed by 
protein precipitation with acetonitrile. Human stool samples were provided homogenized and dried. 10 
mg of stool were processed in 0.1 mL of 0.1M Sodium Hydroxide (pH 13) for 1 hour at 60oC. Samples 
were vortexed intermittently every 20 minutes. 200 microliters of freezer-cold (-20oC) 100% Acetonitrile 
(spiked with IS mix at 400 ng/mL) was added to each sample prior to vortexing at 4oC for 30 minutes. 
Samples were left at -80oC overnight. Precipitate was collected via centrifugation the following morning 
(17,000 x g, 30 min at 4oC). Supernatant (180 uL) was transferred to a 200 uL glass vial insert and vials 
were stored at -80oC until LC-MS analysis.  
LC-MS/MS Analysis:  
LC-MS/MS was performed on a Waters Acquity UPLC coupled to a Waters Xevo TQ-S triple quadrupole 
mass spectrometer. Chromatographic separations were carried out on a Waters T3 stationary phase (1 x 
100 mm, 1.7 μM) column. Mobile phases were Acetonitrile (B) and water with 0.1% formic acid (A). The 
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analytical gradient was as follows: time = 0 min, 30% B; time = 1 min, 30% B; time = 11 min, 97% B; 
time = 12 min, 97% B; time 12.05 min, 30% B; time = 15 min, 30% B. Flow rate was 200 μL/min and 
injection volume was 2.0 μL. Flow rate was 800 μL/min and injection volume was 0.5 μL. Samples were 
held at 4°C in the autosampler, and the column was operated at 45° C. The MS was operated in selected 
reaction monitoring (SRM) mode, where a parent ion is selected by the first quadrupole, fragmented in 
the collision cell, then a fragment ion selected for by the third quadrupole. Product ions, collision 
energies, and cone voltages were optimized for each analyte by direct injection of individual synthetic 
standards. Inter-channel delay was set to 3 ms. The MS was operated in negative ionization modes with 
the capillary voltage set to 2.1 kV respectively. Source temperature was 150° C and desolvation 
temperature 500°C. Desolvation gas flow was 1000 L/hr, cone gas flow was 150 L/hr, and collision gas 
flow was 0.2 mL/min. Nebulizer pressure (nitrogen) was set to 7 Bar. Argon was used as the collision 
gas. A calibration curve was generated using authentic standards for each compounds and their 
corresponding stable isotope labeled internal standards in neat solution.  
Statistical Analysis 
 
Power was calculated using Lenth’s Java Applet for Power and Sample Size40. To achieve 
b=80%, with an R2 of 0.5 on 2 regressors, a sample size of 21 was required. Post, rather than pre, 
intervention data was utilized for one female subject (for short chain fatty acids) due to lack of raw stool 
from baseline. Data was assessed for normality using Q-Q plots. One outlier was detected based on its 
large Cook’s D value for short chain fatty acids, and removed for further analyses. For 9 bile acids, levels 
below the detectable limit were replaced with 50% of the limit of detection value.  
Univariate associations between PA and bile acids and short chain fatty acids were explored using 
Pearson correlations, separately for participants consuming a high fiber, vs. low fiber diet (based on 
median split for dietary fiber intake of 23.194 g/day). Specific bile acids (butyrate, and propionate), and 
short chain fatty acids (DCA, UDCA) were selected based on previous studies suggesting their 
implication in colorectal cancer prevention, ability to be modified by physical activity. 
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Each were plotted with their respective physical activity predictor and dietary fiber (high or low) 
(GraphPad Prism (Version 8).  
Separate multivariable linear regression models were used to examine associations between 
activPAL variables and short chain fatty acids and bile acids, with dietary fiber as a covariate. Several 
other variables such as BMI, waist circumference, total cholesterol, HDL-cholesterol, LDL- cholesterol, 
and dietary fat intake were considered as covariates but we lacked statistical power to use >2 predictors 
and based on univariate correlations, no significant relationships existed between these parameters with 
any physical activity outcomes (p>.05). Statistical analyses were performed using R software.   
  
 





Of the 68 individuals assessed for eligibility, 21 were eligible and completed the food log, fasted 
blood draw, stool sample, anthropometry, and 7-days of accelerometer wear. The most common reason 
for exclusion was disinterest in completing the dietary intervention. Figure 1 shows flow of participants 
through recruitment, eligibility screening, enrollment, and analyses. Participants were a mean age of 
58.95 (SD=8.56) years, mostly Caucasian, and evenly split male/female. Most participants were 
overweight (50%), and the average BMI was 28.14 ± 3.35 kg/m2. All participants achieved a minimum of 
150 minutes of MVPA per week (i.e., meeting physical activity guidelines).41 Additional participant 
characteristics and means and standard deviations for physical activity are shown in Table 1. Means and 
standard deviations of short chain fatty acids in raw stool and bile acids in lyophilized stool in µg/g are 
shown in Table 2 .  
Table 1: Participant Characteristics (n=21) 
  Mean (SD) unless otherwise noted 
Age 58.95 (8.56) 
Sex, female % 48% 
Caucasian % 76% 
BMI 28.14 (3.35) 
Waist Circumference (in) 36.81 (3.62) 
Years since polyp removal 1.8 (1.4) 
Cancer Stage (n, %)   
0 18 (86%) 
I 3 (14%) 
Dietary Fiber Intake (g/day) 24.99 (10.83) 
MET-hours (per day) 22.67 (2.02) 
MVPA (min/day) 71.13 (23.50) 
Guideline minutes (min/day) 20.71 (22.63) 
Light activity (min/day) 268.24 (76.70) 
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Table 2: Short Chain Fatty Acid and Bile Acid Abundances 
  
  Mean, µg/g (SD) 
Short Chain Fatty Acids   
Acetic Acid 1972 (1344) 
Propionic Acid 556.2 (374.5) 
Butyric Acid 439.2 (341.3) 
Isobutyric Acid 92.27 (87.29) 
Isovaleric Acid 88.33 (92.25) 
Valeric Acid 96.20 (91.85) 
Primary Bile Acids   
Cholic Acid 69.31 (115.4) 
Taurocholic Acid 0.9548 (0.89) 
Glycocholic Acid 2.77 (5.30) 
Chenodeoxycholic Acid 30.46 (62.07) 
Glycochenodeoxycholic Acid* 4.62 (6.13) 
Secondary Bile Acids   
Deoxycholic Acid 493.2 (320.7) 
Ursodeoxycholic Acid* 11.65 (19.33) 
Lithocholic Acid 1567 (1055) 
Nutriacholic Acid 275.0 (345.1) 
7alpha-Hydroxy-3-oxo-5beta-cholan-24-oic acid* 40.26 (35.93) 
Hyodeoxycholic Acid* 15.84 (37.38) 
3_Oxocholic Acid* 1.368 (2.160) 
3alpha-6beta-7beta-trihydroxycholenoic acid* 2.401 (5.280) 
Glycodeoxycholic Acid* 1.680 (4.350) 
3beta-hydroxy-5- cholenoic acid* 2.768 (4.018) 
Sulfolithocholic Acid* 26.73 (86.18) 
Taurodeoxycholic Acid 1.083 (0.8030) 




Short Chain Fatty Acids and Physical Activity 
 
Univariate analyses found that average daily minutes of light intensity physical activity were 
positively associated with butyrate (r=0.5791, p=0.007), and propionate (r=0.6818, p=0.0009). Fiber 
alone was negatively correlated with propionate (r= 0.4926, p=0.027) but unrelated to butyrate (r= 0.3422 
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, p=0.14). There was a stronger correlation between propionate and light intensity minutes for low fiber 
consumers (r=0.7909, p=0.006) compared to high fiber consumers (r=0.445, p=0.1976).  There were no 
statistically significant differences between high and low fiber consumers for butyrate (Figure 2). 
Table 3 shows multivariate associations between short chain fatty acids and physical activity 
variables. Daily minutes of light intensity physical activity was significantly and positively associated 
with butyrate [F(2, 17)=5.684, p=0.014, R2=0.3992, and propionate [F(2,17)=13.62, p=0.0003, 
R2=0.6157] while controlling for dietary fiber intake. More specifically, each additional minute per day of 
light intensity activity was associated with 1.88 µg/g higher butyrate concentration (b=1.88, 95%CI 0.477 
to 3.291) and 1.79 µg/g higher propionate concentration (b=1.79, 95%CI 0.862 to 2.724).  There were no 
associations between MET-hours, MVPA, and sedentary minutes and butyrate or propionate 
concentrations. 
 
Bile Acids and Physical Activity 
 
Univariate analyses found that moderate to vigorous physical activity was negatively associated 
with deoxycholic acid (r=0.4468, p=0.042), and ursodeoxycholic acid (r=0.5579, p=0.009). Fiber alone 
was unrelated to deoxycholic acid (r= 0.0866, p=0.71) and ursodeoxycholic acid (r= 0.077, p=0.75). 
There was a stronger correlation between between ursodeoxycholic acid and light intensity minutes for 
high fiber consumers (r=0.6283, p=0.04) compared to low fiber consumers (r=0.5681, p=0.09).  There 
were no statistically significant differences between high and low fiber consumers for deoxycholic acid. 
(Figure 3). 
 Table 3 shows multivariate associations between bile acids and physical activity 
variables. After controlling for dietary fiber, minutes of moderate to vigorous physical activity was no 
longer significantly associated with deoxycholic acid [F(2,18)=2.377, p=0.1213, R2=0.209]. However  
MVPA continued to be significantly, inversely associated with ursodeoxycholic acid [F(2,18)=4.213, 
p=.032, R2=.0.3189] after accounting for dietary fiber. Further, each additional minute of MVPA per day 
was associated with 6.13 µg/g lower deoxycholic acid (b=-6.13, 95%CI -12.14 to -0.11) and 0.45 µg/g 
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lower ursodeoxycholic acid concentration (b= -0.45, 95%CI -0.80 to -0.12). There were no associations 
between MET-hours, light intensity physical activity, and sedentary minutes and deoxycholic acid, and 
ursodeoxycholic acid. 
For other primary bile acids (cholic acid, chenodeoxycholic acid, and taurocholic acid), several PA 
predictors (light intensity, MVPA, and MET-hours) were trending toward significance, but no PA 
predictors nor dietary fiber were significant predictors of these bile acids. Table 4 shows select bile acid 
associations for physical activity outcomes measured by activPAL. All remaining bile acid regressions are 
in Supplemental Table 1.  
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Table 3: Associations of ActivPAL-Derived Variables and Dietary Fiber with Short Chain Fatty Acids 
  Butyrate   Acetate   Propionate 
  b (95% CI) p-value   b (95% CI) p-value   b (95% CI) p-value 
Light Intensity Minutes 1.88 (0.480 − 2.39) 0.0117 
 
5.18 (-0.454 − 10.8) 0.0692 
 
1.79 (0.86 −2.72) <0.001 
Dietary Fiber Intake −6.35 (-16.3 − 3.62) 0.1966 
 
−47.59 (-87.5 − -7.70) 0.0222 
 
−8.08 (-14.7 − -1.48) 0.019328 
Whole Model R2= 0.3992 0.01316 
 
R2= 0.4132 0.01077 
 





    
 
    
MVPA Minutes −0.208  (-5.71 −  5.29) 0.937 
 
6.61 (-13.2 −  26.4) 0.4908 
 
−0.341 ( -4.55 − 3.87) 0.866497 
Dietary Fiber Intake −8.50 (-20.4 − 3.43) 0.151 
 
−53.2  (-96.1 − -10.3) 0.01808 
 
−10.1 (-19.3 − -0.993) 0.031791 
Whole Model R2= 0.1174 0.3458 
 
R2= 0.3036 0.04614 
 





    
 
    
MET-Hours 50.4 (-8.96 − 110) 0.091 
 
164 (-56.8 − 384) 0.1356 
 
33.7 (-12.8 − 80.2) 0.145 
Dietary Fiber Intake −6.86 (-18.0 − 4.25) 0.21 
 
−48.2 (-89.4 − -8.86) 0.0249 
 
−9.02 (-17.7 − -0.321) 0.043 
Whole Model R2= 0.2573 0.07977 
 
R2= 0.3738 0.01872 
 





    
 
    
Sedentary Minutes −0.011 (-1.62 − 1.59) 0.988 
 
−0.477 (-6.32 − 5.37) 0.8652 
 
−0.443 (-1.65 − 0.765) 0.4501 
Dietary Fiber Intake −8.46 (-21.0 − 4.08) 0.173 
 
−52.3 (-98.0 − -6.59) 0.0274 
 
−9.04 (-18.5 − -0.408) 0.0596 
Whole Model R2= 0.1171 0.3468   R2= 0.2846 0.05805   R2= 0.2684 0.07016 
  
       
  
  Isobutyrate   Isovalerate   Valerate 
  b (95% CI) p-value   b (95% CI) p-value   b (95% CI) p-value 
Light Intensity Minutes 0.302 (-0.219 −  0.8234) 0.239 
 
 0.330 (-0.222 − 0.882) 0.226 
 
0.404 (-0.132  − 0.939) 0.131 
Dietary Fiber Intake −2.17 (-5.86 − 1.53) 0.234 
 
−2.17 (-6.08 − 1.75) 0.26 
 
−2.17(-5.96 − 1.62) 0.245 
Whole Model R2=  0.1658 0.1957 
 
R2=  0.1622 0.2033 
 
R2=  0.2067 0.1244 
     
 
    
 
    
MVPA Minutes 0.379 (-1.36 − 2.12) 0.652 
 
0.425 ( -1.42 − 2.27) 0.634 
 
 0.395 (-1.44 − 2.22) 0.656 
Dietary Fiber Intake −2.49 (-6.27  − 1.28) 0.182 
 
−2.52 (-6.52 − 1.48) 0.202 
 
−2.62 (-6.58 − 1.36) 0.184 
Whole Model R2=0.1075 0.1075 
 
R2= 0.1007 0.3846 
 
R2= 0.1063 0.3637 
     
 
    
 
    
MET-Hours 8.81 (-11.3 − 28.9) 0.37 
 
9.59 (-11.8 − 30.9) 0.358 
 
11.9 (-8.96 −  32.8) 0.246 
Dietary Fiber Intake −2.23 (-5.99 −  1.54) 0.23 
 
−2.23(-6.22 − 1.76) 0.256 
 
−2.24 (-6.15 − 1.66) 0.243 
Whole Model R2= 0.1376 0.2638 
 
R2= 0.1319 0.2799 
 
R2= 0.163 0.2016 
     
 
    
 
    
Sedentary Minutes −0.0404 (-0.547 −  0.466) 0.869 
 
−0.0701 (-0.607 − 0.467) 0.787 
 
−0.0791 (-0.612 − 0.453) 0.759 
Dietary Fiber Intake −2.41 (- 6.40  − 1.58) 0.22 
 
−2.37(-6.60 − 1.86) 0.254 
 
−2.44 (-6.63 − 1.76) 0.238 
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  Taurocholic Acid 




Minutes −0.601 (-1.29 −0.0880) 0.0836  −0.3191 (-0.68 - 0.044) 0.0814  
−0.00251 (-0.00817 − 
0.003158428) 0.3651 
Dietary Fiber Intake 
−1.74 (-6.62 − 3.15) 0.4647  −1.63 (-4.21- 0.938) 0.1986  −0.00138 (-0.0415 − 0.0387) 0.9432 
Whole Model R2= 0.1653 0.1968 
 
R2= 0.2004 0.1336 
 
R2=0.04609 0.654 
                
MVPA Minutes 
−1.86 (-4.10 − 0.379) 0.0981  −0.9334 (-2.12- 0.256) 0.1164  −-0.0150 (-0.032 − 0.00217) 0.0832 
Dietary Fiber Intake 
−1.14 (-5.99 − 3.72) 0.6287  −1.3138 (-3.90 - 1.27) 0.2991   0.000777 (-0.0364 − 0.0380) 0.9655 
Whole Model R2= 0.1529 0.2246 
 
R2= 0.1739 0.1792 
 





    
 
    
MET-Hours 
−22.5 (-48.7 −3.78) 0.0889  −12.121 (-25.91- 1.67) 0.0813  −-0.180 (-0.382 − 0.0209) 0.076 
Dietary Fiber Intake 
−1.78 (-6.69 − 3.13) 0.4562  −1.663 (-4.24 - 0.915) 0.192  −0.00437 (-0.0420 − 0.0333) 0.81 
Whole Model R2= 0.1605 0.207 
 
R2= 0.2005 0.1334 
 





    
 
    
Sedentary Minutes 
0.341 (-0.340 −1.02) 0.307  0.1985 (-0.158 - 0.555) 0.258  0.000669 (-0.00474 − 0.00608) 0.798 
Dietary Fiber Intake 
−1.89 (-7.25 −3.48) 0.469  −1.7571 (-4.57 - 1.05) 0.205  −0.000159 (-0.0427 − 0.0424) 0.994 
Whole Model R2 =0.067 0.5357   R2= 0.1161 
0.3292
5 
 R2=0.004067 0.964 
  
       
 
  Deoxycholic Acid   Ursodeoxycholic Acid   
  b (95% CI) p-value   b (95% CI) p-value    
Light Intensity 
Minutes −0.387 ( -2.47 −  1.69) 0.7005  
−0.0688 (-0.190 − 
0.0526) 0.2492  
  
Dietary Fiber Intake 
−-3.02 (-17.7 −  11.7) 0.6723  −0.214 ( -1.07 − 0.647) 0.6081  
  
Whole Model R2=  0.01591 
0.8656  
R2=  0.07831 
0.48  
  
      
 




−6.125 (-12.1 −  -
0.114) 
0.0462
3  −0.461 (-0.797− -0.124) 0.01  
  
Dietary Fiber Intake 
−2.864  (-15.9 −  10.2) 
0.6502
4  − 0.157 (-0.887 − 0.573) 0.6572  
  






      
 




−61.85 (-135 − 11.4) 0.0929  −-4.45(-8.71 − -0.203) 0.041  
  
Dietary Fiber Intake 
−-4.582  (-18.3 −  
9.11) 0.4909  −0.280 (-1.07 − 0.515) 0.4694  
  
Whole Model R2=0.15543 
0.2188  
R2= 0.2166 0.111 
 
  
      
 




0.0807 (--1.87 −  2.03) 0.932  0.0627 (-0.0510 − 0.176) 0.262  
  
Dietary Fiber Intake 
−2.78 (-18.1 − 12.6) 0.709  −-0.289 (-1.18 − 0.606) 0.506  
  
Whole Model R2= 0.00797 
0.9305 
  R2= 0.07471 
0.4972 

















Figure 2. Correlations between light intensity minutes per day with fecal butyrate and propionate. (a) Positive 
correlation between light intensity minutes and fecal butyrate (r=0.5791, p=0.007) with dietary fiber separated by 
median value. (b) Positive correlation between light intensity minutes and fecal propionate (r= 0.6818, p=0.0009) with 
dietary fiber separated by median value. 
(a) (b) 
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Figure 3. Correlations between MVPA minutes per day with fecal deoxycholic acid and ursodeoxycholic acid. 
(a) Negative correlation between MVPA minutes and fecal deoxycholic acid  (R2=0.4468, p=0.04) with dietary fiber 
separated by median value. (b) Negative correlation between MVPA minutes and fecal ursodeoxycholic acid  
(R2=0.5579, p=0.009) with dietary fiber separated by median value.
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The aim of this study was to examine the relationships between physical activity and the stool 
metabolome in individuals at high risk for colorectal cancer. This is the first study to test associations of 
both endogenous and microbial derived stool metabolites and physical activity in individuals at high risk 
for colorectal cancer. Both butyrate and propionate were positively correlated with light intensity physical 
activity when accounting for dietary fiber intake. Conversely, both deoxycholic and ursodeoxycholic acid 
were negatively correlated with MVPA when accounting for dietary fiber intake. These findings suggest 
that both moderate to vigorous intensity physical activity and light intensity physical activity may be 
important for colorectal cancer primary and secondary prevention through different mechanisms.  
 
Relationships between Physical Activity and Fecal Short Chain Fatty Acids 
This study found that there was a positive correlation between butyrate and propionate and light 
intensity physical activity when accounting for dietary fiber intake. Similarly, rodent studies have 
suggested that voluntary exercise increases butyrate concentration in the cecum,42 and in humans, Allen et 
al21 (2018) found that a 6-week exercise intervention in previously sedentary but healthy individuals led 
to increases in short chain fatty acid producing species as well as increased absolute abundance of short 
chain fatty acids in lean individuals.  
Several mechanisms could explain why physical activity may alter fecal short chain fatty acids. 
One mechanism would simply be mixing of intestinal contents during exercise and thus more surface area 
for bacterial fermentation of fiber.43 A second mechanism could be increased anaerobic fermentation due 
to reduced colonic oxygen saturation during exercise.43 Additionally, exercise is associated with colonic 
pH changes which may select for certain bacterial genera, and this can decrease transformation of primary 
bile acids to secondary bile acids.44 Physical activity also increases gut motility which could result in 
increased excretion, rather than absorption, of short chain fatty acids.44 Finally, exercise induces increased 
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expression of bacterial butyrate-acetoacetate CoA-transferase (BCoAT). BCoAT transfers co-A from 
butyrlcoA to acetate which forms butyrate and acetyl coA.21 No previous studies have showed a 
relationship between light, but not moderate to vigorous, physical activity and stool short chain fatty 
acids. This could be due to gastrointestinal upset due to vigorous activity45 that may cause a pro-
inflammatory immune response and thus blunt the production of short chain fatty acids. Furthermore, this 
could be unique to those at high risk for colorectal cancer survivors and thus be an important 
consideration for exercise prescription for these individuals.  
Weir et al (2013) found that colorectal cancer survivors had significantly lower percentage of 
butyrate in their stool compared to healthy controls as well as higher percentages of acetic, valeric, 
isobutyric, isovaleric acids46. Furthermore, there were fewer butyrate producing bacterial species in the 
colorectal cancer survivors compared to healthy controls.  However, it is unknown if this is due to cancer 
or cancer treatment versus being causative of cancer.  Butyrate and propionate, but not acetate, inhibit 
histone deacetylases in immune cells and colonocytes. This results in downregulation of pro inflammatory 
cytokines. Butyrate and propionate also are involved in anti-inflammatory effects that regulate colonic 
regulatory T cells.47 We showed a relationship between light intensity activity and butyrate and 
propionate, but not acetate. This is a potential important mechanistic link between physical activity and 
colorectal cancer prevention.  
 
Relationships between Physical Activity and Fecal Bile Acids 
The current study found that there was a negative correlation between ursodeoxycholic acid and 
deoxycholic acid and moderate to vigorous physical activity, although this was not significant for 
deoxycholic acid when accounting for dietary fiber intake. This finding is different from a previous study 
by Wertheim et al (2012), who found that colorectal cancer survivors who were in the lowest quartile of 
recreational physical activity duration had a 17% lower fecal bile acid concentration compared to the 
highest quartile. Thus, based on the preliminary data from this study, it is uncertain whether the pattern 
exists in those who are at high risk for colorectal cancer (but do not have cancer). Imray et al (1992) 
 
  21 
found that individuals who had adenomatous polyps removed had higher concentrations of secondary 
fecal bile acids than healthy controls.48 Furthermore, those with colorectal cancer had higher total bile 
acids and primary bile acids in their stool compared to both healthy controls and those who underwent 
adenomatous polyp removal. It is unknown whether or not physical activity can mediate this relationship. 
Secondary bile acids, in particular deoxycholic acid and lithocholic acid, may be cancer-promoting 
through several different mechanisms. They both cause cell membrane damage resulting in destruction of 
intestinal epithelium. Additionally, these secondary bile acids cause cell proliferation through epidermal 
growth factor receptors (EGFRs) and post-EGFR/ERK (extracellular signal-related kinase) signaling. 
Finally, they lead to increased reactive oxygen species and reactive nitrogen species through activation of 
NADH and NADPH oxidases and phospholipase A2 and activation of NF-kB which is important in 
cellular processes such as apoptosis and inflammation.49 The present study found a negative correlation 
between ursodeoxcholic acid and moderate to vigorous physical activity. Consequently, ursodeoxycholic 
acid may be a chemoprotective agent against colorectal cancer. In a study of 21,000 adults, those who 
supplemented ursodeoxycholic acid had significantly reduced risk of cancer (HR 0.60, 95% CI 0.39-
0.92).25 Mechanistically, it may suppress deoxycholic-acid induced apoptosis and deoxycholic acid-
induced epidermal growth factor activation.  
           Taurocholic acid, a primary bile acid, is also known to be genotoxic and pro-inflammatory. It can 
lead to an increase in Bilophilia wadsworthia which can lead to an accumulation of H2S which may be 
cancer promoting.50 In the current study we saw a trending negative relationship between taurocholic acid 
and moderate to vigorous physical activity (p=0.07).  
 Reverse cholesterol transport may be the mechanism responsible for exercise-induced reductions 
in stool bile acids.26,51 Lecithin -cholesterol acyltransferase may be upregulated by physical activity and 
thus increasing reverse cholesterol transport. Bile acids interact with gut epithelial cell receptors faenesoid 
X receptor (FXR) and TGR5. This can alter glucose, lipid, and energy homeostasis. This could be a link 
between physical activity and bile acid metabolism, mediated by the microbiome.52 
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Most of the inflammatory and/or carcinogenic bile acids are secondary bile acids. It is unknown how 
physical activity modulates microbes with genes for bile salt hydrolase and/or 7-a hydroxylase that 
convert primary bile acids to secondary bile acids. More work must be done to elucidate the effects of 
physical activity on the microbiome, in particular deoxycholic acid producing microbes.  
Strengths and Limitations 
 
Two limitations of this study are the cross sectional design as well as the highly active population 
whom all met physical activity guidelines. This population lacked variability and it is unknown the 
threshold at which physical activity may modulate bile acids and short chain fatty acids. Furthermore, 
BMI, cholesterol, and dietary fat intake could be meaningful predictors of these outcomes but we lacked 
the sample size to add these to the models. Other studies have stratified by BMI and plasma triglycerides 
but we lacked the sample size to do so.  Due to its self-report nature, dietary fiber intake could have been 
inaccurate due to inaccurate food logs. Finally, these results from microbial-derived metabolites could be 
augmented with microbiome analysis which is not reported in this paper.  
There are several strengths of this study. This is the first study to test associations of both 
endogenous and microbial derived stool metabolites and physical activity in individuals at high risk for 
colorectal cancer. Additionally, many studies use self-reported physical activity and we used objectively 
measured physical activity. Finally, all intensities of physical activity were measured which provides a 





In conclusion, these data provide evidence that both MVPA and light intensity physical activity 
may reduce bile acids, and increase short chain fatty acids, respectively after controlling for dietary fiber 
intake. This study is an important step in understanding the mechanistic relationship between physical 
activity and colorectal cancer risk, with an emphasis on microbial derived metabolites. Additional insight 
from large physical activity intervention trials in sedentary individuals at high risk for colorectal cancer 
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are necessary to clarify and/or confirm these findings. An increase in physical activity could induce 
similar modulations to these metabolites. If confirmed, a spectrum of physical activity intensity may be 
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This study was underpowered to utilize all predictors that may be necessary to predict fecal bile 
acids. For deoxycholic acid and moderate to vigorous physical activity with 4 regressors (moderate to 
vigorous physical activity, dietary fiber intake, BMI, and plasma triglycerides) based on an R2 of 0.209 
(f2=0.2642), with p=0.05 and 80% power, a sample size of 51 would be required. 
Furthermore, a more practical measure of these outcomes would be an exercise intervention in 
previously sedentary individuals at high risk for colorectal cancer. Based on the findings in the current 
study, the intervention could use a spectrum of physical activity intensity due to the differential effects on 
fecal short chain fatty acid and bile acids.  
Finally, fecal measures, while practical to collect, are not an accurate representation of colon 
metabolism. A more accurate representation could be colon tissue collected during a colonoscopy. These 
same measures could be repeated on colon tissue to examine the effects of physical activity on short chain 
fatty acids and bile acids.  
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Supplementary Table 1: Associations of ActivPAL-Derived Variables and Dietary Fiber with Bile Acids 
  Lithocholic Acid   Nutriacholic Acid   
7alpha-Hydroxy-3-oxo-5beta-cholan-
24-oic acid 
  b (95% CI) 
p-
value 
  b (95% CI) p-value   b (95% CI) p-value 
Light Intensity 
Minutes −1.028 ( -7.90 - 5.85) 0.757  
−1.223 ( -3.36 -  0.915) 0.245 
 
−0.17582 (-0.394 - 0.0428) 0.1084 
Dietary Fiber Intake −4.182 (-52.90 - 44.5) 0.859  4.223 (-10.9 - 19.4) 0.565  0.02486 (-1.52 - 1.57) 0.9735 
Whole Model R2=  0.006396 0.9439  R2= 0.1031 0.3757  R2= 0.1408 0.2551 
                
MVPA Minutes  -12.631 (-7.90 - 5.85) 0.2291  −5.530 ( -12.1 - 1.08) 0.096  −0.1043 (-0.861 - 0.652) 0.775 
Dietary Fiber Intake −3.603 (-52.9 - 44.5) 0.8719  5.36 ( -8.99 - 19.7) 0.4431  0.2209 (-1.42 - 1.86) 0.781 
Whole Model R2=0.08016 0.4714  R2= 0.1729 0.1812  R2= 0.009222 0.92 
                
MET-Hours −100.065 (-357 - 157) 0.424  −57.096 (-137 - 22.4) 0.149  −1.9551(-10.8 - 6.92) 0.649 
Dietary Fiber Intake −6.254  (-54.3 - 41.8) 0.788  3.769 (-11.1 - 18.6) 0.601  0.1624 (-1.50 - 1.82) 0.84 
Whole Model R2=0.03673 0.714  R2= 0.1399 0.2577  R2=  0.01628 0.8627 
                
Sedentary Minutes 0.8406 (-5.59 - 7.27) 0.787  0.7743 ( -1.27 -  2.82) 0.436  0.17426(-0.0280 - 0.377) 0.0871 
Dietary Fiber Intake −-5.0703 ( -55.7 - 45.6) 0.836  3.7206 ( -12.4 - 19.8) 0.633  −0.20196 (-1.79 - 1.39) 0.793 
Whole Model R2= 0.005121 0.9548   R2= 0.06413 0.5507   R2= 0.1578 0.2131 
           
  Hyodeoxycholic Acid   3_Oxocholic Acid   
3alpha-6beta-7beta-
trihydroxycholenoic acid 
  b (95% CI) 
p-
value 
  b (95% CI) p-value   b (95% CI) p-value 
Light Intensity 
Minutes 








−0.02310 (-0.0554 - 
0.00920) 
0.1503 
Dietary Fiber Intake −0.09014 (-1.71 - 1.53) 0.908  −0.018560 (-0.116 - 0.0785) 0.693  −0.08703 (-0.316 - 0.142) 0.4347 
Whole Model R2= 0.1243 0.3028  R2= 0.06031 0.5713  R2= 0.1252 0.3002 
               
MVPA Minutes −0.275 ( -1.05 - 0.500) 0.465  −0.03014 (-0.0731 - 0.0128) 0.158  −0.04720 (-0.155 - 0.0607) 0.37 
Dietary Fiber Intake 0.09515 (-1.59 - 1.78) 0.907  −0.01216 (-0.105 - 0.0811) 0.787  −0.06285(-0.297 - 0.171) 0.58 
Whole Model R2= 0.03092 0.7538  R2= 0.1102 0.3496  R2= 0.05959 0.5752 
               
MET-Hours −0.03219 (-9.31 -  9.25) 0.994  −0.06675 (-0.602 - 0.468) 0.796  −0.08383 (-1.38 - 1.22) 0.894 
Dietary Fiber Intake 0.1071 (-1.63 - 1.84) 0.898  −0.01290 (-0.113 -  0.0871) 0.79  −0.06334 (-0.306 - 0.180) 0.591 
Whole Model R2= 0.0009841 0.9912  R2= 0.006679 0.9415  R2= 0.01646 0.8613 
               
Sedentary Minutes 




0.013064 (0.00156 - 0.0246) 0.0282 
 
0.03149 (0.00351 - 0.0595) 0.0295 
Dietary Fiber Intake −0.38800 (-2.00 - 1.23) 0.6203  −0.042809 (-0.133 - 0.0478) 0.3339  −0.13792(-0.358 - 0.0823) 0.2048 
Whole Model R2= 0.1927 0.1456   R2= 0.2425 
0.0821
6 
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Supplementary Table 1 continued: Associations of ActivPAL-Derived Variables and Dietary Fiber with Bile Acids 
  Glycodeoxycholic Acid   3beta-hydroxy-5- cholenoic acid   Glycochenodeoxycholic Acid 
  b (95% CI) p-value   b (95% CI) p-value   b (95% CI) p-value 
Light Intensity 
Minutes 
0.0004682 (-0.0272 - 
0.0281) 0.972  




−0.02581(-0.0633 - 0.0112) 0.1658 
Dietary Fiber Intake 
−0.0946338 (-0.290 - 
0.101) 0.324  
0.169352 (0.00699 - 0.332) 0.0418 
 
−0.11767 (-0.384 - 0.148) 0.3649 
Whole Model R2=  0.05617 
0.5944  
R2=  0.2398 
0.0847
8  
R2=  0.1255 0.299 
                
MVPA Minutes 
−0.004707 (-0.0937 - 
0.0843) 0.913  
0.01183 (0.0624 - 0.0861) 0.7417 
 
−0.0720 (-0.195 - 0.0507) 
0.2334 
Dietary Fiber Intake 
−0.095391(-0.289 - 
0.0979) 0.314  
0.17702 (0.0158 - 0.338) 0.0332 
 
−0.09156 (-0.359 - 0.175) 
0.4793 
Whole Model R2=  0.05675 
0.5911  
R2=  0.2309 
0.0941
8  R2=  0.1002 0.3866 
                
MET-Hours −0.38887 (-1.42 - 0.643) 
0.439  
0.0812 (-0.796 - 0.958) 0.848 
 
−1.7030 (-2.95 -  -0.4556) 
0.0102
2 
Dietary Fiber Intake −0.10779(-0.301 - 0.0852) 
0.256  
0.1791(0.0151 -  0.343) 0.034 
 
−0.1434 (-0.377 - 0.0898) 
0.2126
6 
Whole Model R2=  0.08786 
0.4371  
R2=  0.2277 
0.0977
3  
R2=  0.3303 
0.0271
1 
                
Sedentary Minutes 
−0.01178 (-0.0369 - 
0.0134) 0.339  




−0.07200 (-0.0484 - 0.0248) 0.2334 
Dietary Fiber Intake −0.06625(-0.264 - 0.132) 0.491  0.148327 (-0.0159 - 0.313) 0.0738  −0.09156 ( -0.347 - 0.229) 0.4793 
Whole Model 
R2=  0.1042 0.3715 
  R2=  0.2795 
0.0523
6 
  R2=  0.1002 0.6391 
           
  Sulfolithocholic Acid   Glycocholic Acid   Taurodeoxycholic Acid 
  b (95% CI) p-value   b (95% CI) p-value   b (95% CI) p-value 
Light Intensity 
Minutes 
−0.2799 (-0.826 - 0.266) 0.296 
 




0.0001108 (-0.00489 - 
0.00511) 
0.9634 
Dietary Fiber Intake −0.7047 (-4.57 - 3.16) 0.706  −0.10384 (-0.331 -  0.124) 0.3501  −0.0226531(-0.0581 - 0.0128) 0.1961 
Whole Model R2=  0.06276 0.558  R2=  0.1442 0.2462  R2=  0.09429 0.4101 
               
MVPA Minutes −1.4133 (-3.09 - 0.260) 0.093 
 
−0.05140 (-0.159 - 0.0561) 0.3283 
 
−0.010100 (-0.0254 - 0.00522) 
0.1830
4 
Dietary Fiber Intake −0.4514 (-4.08 -  3.18) 0.797 
 
−0.07849 (-0.312 - 0.155) 0.4887 
 
−0.023257 (-0.0565 - 0.0100) 
0.1591
2 
Whole Model R2=  0.1508 0.2297  R2= 0.07595 0.4912  R2= 0.1814 0.1651 
               
MET-Hours −26.540 (-43.4 -  -9.67) 
0.0039
3  
−0.61326 (-1.88 - 0.652) 0.322 
 
−0.12299 (-0.303 - 0.0570) 0.1682 
Dietary Fiber Intake −1.246 (-4.40 - 1.91) 
0.4173
8  
−0.09597 (-0.333 - 0.141) 0.405 
 
−0.02677 (-0.0604 - 0.00688) 0.1119 
Whole Model R2=  0.3792 0.0137 
 
R2=  0.07722 0.4852  R2=  0.1873 0.1547 
               
Sedentary Minutes −0.16577 (-0.686 - 0.354) 0.511 
 




−0.0004546 (-0.00513 - 
0.00422) 
0.84 
Dietary Fiber Intake 0.02228 (-4.07 -  4.12) 0.991  −0.12652 (-0.366 - 0.113) 0.281  −0.0216637 (-0.0584 - 0.0151) 0.232 
Whole Model R2=  0.02661 0.7845   R2=  0.1226 0.3083   R2=  0.09628 0.4021 
 
